Viruses. 2023 Apr 29;15(5):1099.doi: 10.3390/v15051099.

中文速读

本研究使用Engreen的Entranster-R4000转染试剂将AT149(5'PPP dsRNA)转染至HEK293细胞,验证其通过RIG-I受体激活先天免疫,并作为佐剂与SARS-CoV-2 Delta-Omicron嵌合RBD二聚体重组蛋白疫苗联合免疫小鼠,显著提高免疫原性和交叉中和抗体水平。

小鼠HEK-Lucia Null cells with RIG-I overexpressionHEK-Lucia Null cells with RIG-I knockoutHEK-Lucia Null cells RIG-I Null

本文使用:小核酸转染试剂Entranster™-R4000

查看产品详情(含全部 223 篇文献) →

A Novel Targeted RIG-I Receptor 5’Triphosphate Double Strain RNA-Based Adjuvant Significantly Improves the Immunogenicity of the SARS-CoV-2 Delta-Omicron Chimeric RBD-Dimer Recombinant Protein Vaccine

Affiliations

Affiliations

  • 1 Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Control, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing 102600, China.
  • 2 Shanghai JunTuo Biotechnology Co., Ltd., Shanghai 201210, China.
  • 3 Beijing Minhai Biotechnology Co., Ltd., Beijning 102600, China.

Free PMC article

Abstract

The rapid mutation and spread of SARS-CoV-2 variants recently, especially through the emerging variants Omicron BA5, BF7, XBB and BQ1, necessitate the development of universal vaccines to provide broad spectrum protection against variants. For the SARS-CoV-2 universal recombinant protein vaccines, an effective approach is necessary to design broad-spectrum antigens and combine them with novel adjuvants that can induce high immunogenicity. In this study, we designed a novel targeted retinoic acid-inducible gene-I (RIG-I) receptor 5’triphosphate double strain RNA (5’PPP dsRNA)-based vaccine adjuvant (named AT149) and combined it with the SARS-CoV-2 Delta and Omicron chimeric RBD-dimer recombinant protein (D-O RBD) to immunize mice. The results showed that AT149 activated the P65 NF-κB signaling pathway, which subsequently activated the interferon signal pathway by targeting the RIG-I receptor. The D-O RBD + AT149 and D-O RBD + aluminum hydroxide adjuvant (Al) + AT149 groups showed elevated levels of neutralizing antibodies against the authentic Delta variant, and Omicron subvariants, BA1, BA5, and BF7, pseudovirus BQ1.1, and XBB compared with D-O RBD + Al and D-O RBD + Al + CpG7909/Poly (I:C) groups at 14 d after the second immunization, respectively. In addition, D-O RBD + AT149 and D-O RBD + Al + AT149 groups presented higher levels of the T-cell-secreted IFN-γ immune response. Overall, we designed a novel targeted RIG-I receptor 5’PPP dsRNA-based vaccine adjuvant to significantly improve the immunogenicity and broad spectrum of the SARS-CoV-2 recombinant protein vaccine.

Keywords: immunogenicity; recombinant protein vaccine; retinoic acid-inducible gene-I (RIG-I) receptor; vaccine adjuvant.

本文使用的产品

小核酸转染试剂Entranster™-R4000

已有 223 篇已发表文献

查看产品详情(含全部 223 篇文献) →

热线电话
  • 010-60535354
微信客服二维码 微信扫一扫,加微信客服
0
0
我的购物车
购物车是空的去下单